The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer PRISM-1, the ongoing registrational, Phase 3 study evaluating quemliclustat plus chemotherapy as a first ...

PRISM-1, the ongoing registrational, Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer, is expected to be fully enrolled by the ...

Quemliclustat is being co-developed with Gilead Sciences and works by blocking the production of adenosine, which can suppress immune responses against tumors. The company noted that quemliclustat ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

(RTTNews) - Arcus Biosciences, Inc. (RCUS) Thursday said that its quemliclustat was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic ...

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a biotechnology company with a strong balance sheet showing more cash than debt according to InvestingPro data, announced Thursday that its ...